Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis

New England Journal of Medicine

Volumn 362, Issue 2, 2010, Pages 118-128

  Griffiths, Christopher E M ^a   Strober, Bruce E ^b   Van De Kerkhof, Peter ^c   Ho, Vincent ^d   Fidelus Gort, Roseanne ^e   Yeilding, Newman ^f   Guzzo, Cynthia ^f   Xia, Yichuan ^f   Zhou, Bei ^f   Li, Shu ^f   Dooley, Lisa T ^f   Goldstein, Neil H ^g   Menter, Alan ^h  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^e Experimental Station   (United States)

^f CENTOCOR INC   (United States)

^g Precision Research   (United States)

^h BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALEFACEPT; CYCLOSPORIN; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; METHOTREXATE; USTEKINUMAB;

ACUTE KIDNEY FAILURE; ADULT; ANAPHYLAXIS; APPENDICITIS; ARTICLE; BACKACHE; BACTERIAL MENINGITIS; BODY SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTRITIS; GASTROINTESTINAL INFECTION; HEART INFARCTION; HOSPITAL INFECTION; HUMAN; HYPERTENSION; INJECTION SITE REACTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYCOSIS FUNGOIDES; NEPHROLITHIASIS; PALATE DISEASE; PANCREATITIS; PEPTIC ULCER BLEEDING; PHASE 3 CLINICAL TRIAL; PHOTOTHERAPY; PHYSICIAN; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PSORIASIS; PSYCHOSIS; PUVA; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SERUM SICKNESS; SHOULDER IMPINGEMENT SYNDROME; SKIN CANCER; THORAX PAIN; TREATMENT DURATION; ULTRAVIOLET B RADIATION; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; UVULITIS;

EID: 74249094930     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa0810652     Document Type: Article

References (28)

1. Schön MP, Boehncke W-H. Psoriasis. N Engl J Med 2005;352:1899-912.
2. Griffiths CEM, Barker JNWN. Pathogenesis and clinical features of psoriasis. Lancet 2007;370:263-71.
3. Heydendael VMR, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporine in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65.
4. Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22.
5. Lebwohl M, Tyring SK, Hamilton TK, et al. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003;349:2004-13.
6. Lebwohl M, Christophers E, Langley R, Ortonne JP, Roberts J, Griffiths CEM. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003;139:719-27.
7. Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension study. J Am Acad Dermatol 2006;55:598-606.
8. Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74.
9. Menter AM, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;56:31. e1-31.e15.
10. Hehlgans T, Pfeffer K. The intriguing biology of the tumour necrosis factor/tumor necrosis factor receptor superfamily: players, rules and the games. Immunology 2005;115:1-20.
11. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005;175:2721-9.
12. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
13. Steinman L. A rush to judgment on Th17. J Exp Med 2008;205:1517-22.
14. McKenzie BS, Kastelein RA, Cua DJ. Understanding the IL-23-IL-17 immune pathway. Trends Immunol 2006;27:17-23.
15. Vanden Eijnden S, Goriely S, De Wit D, Willems F, Goldman M. IL-23 up-regulates IL-10 and induces IL-17 synthesis by polyclonally activated naive T cells in human. Eur J Immunol 2005;35:469-75.
16. Caproni M, Antiga E, Melani L, Volpi W, Del Bianco E, Fabbri P. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized-controlled trial. J Clin Immunol 2009;29:210-4.
17. + effector memory T cells. J Immunol 2008;180:7948-57.
18. Acosta-Rodriguez EV, Napolitani G, Lanzavecchia A, Sallusto F. Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17-producing human T helper cells. Nat Immunol 2007;8:942-9.
19. Leonardi CL, Kimball AB, Papp KA, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74.
20. Kimball AB, Gordon KB, Langley RG, Menter A, Chartash EK, Valdes J. Safety and efficacy of ABT-874, a fully human interleukin-12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7.
21. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
22. Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
23. Saurat J-H, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66.
24. Ouyang W, Kolls JK, Zheng Y. The biological functions of T helper 17 cell effector cytokines in inflammation. Immunity 2008;28:454-67.
25. + T cell trafficking and development by IFN-γ: mechanism and pathological relevance in psoriasis. J Immunol 2008;181:4733-41.
26. Liu Y, Helms C, Liao W, et al. A genome-wide association study of psoriasis and psoriatic arthritis identifies new disease loci. PLoS Genet 2008;4(3):e1000041.
27. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92.
28. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84.